CSI Market
Sign In | Register

Chemomab Therapeutics Ltd (CMMB) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CMMB Annual Cash Flow →
Looking at cash flow data from Chemomab Therapeutics Ltd through Dec 31 2024 provides insight into Dec 31 2025's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-9.00
Depreciation & amortization0.07
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.04
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.62
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Adjustments For Finance Costs Net-
Income Tax Expense Benefit-
Capital Loss-
Income taxes2.92
Losses/ -gains on Investments net0.00
Increase (Decrease) in Employee Related Liabilities-0.28
Increase (Decrease) in Accounts Payable, Trade-0.18
Increase (Decrease) in Accrued Liabilities-1.20
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.14
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.04
Discontinued operations0.00
Net Cash flow from Operating Activities-11.13
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Proceeds from Sale of Other Assets, Investing Activities0.00
Other Net5.39
Discontinued operations0.00
Net Cash Flow from Investing Activities5.39
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock7.15
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-6.15
Payment Of Financing And Stock Issuance Cost-
Cash Acquired In Reverse Recapitalization-
Proceeds From Receivables On Account Of Shares-
Cash Acquired In Merger-
Issuance Of Shares Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Income Taxes Received-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities7.16
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-11.13
Total Cash Flow1.42
4 historic quarters locked

Sign in to unlock the full Chemomab Therapeutics Ltd cash flow history.

Sign In Create Free Account

About Chemomab Therapeutics Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

  • Form: 20-F (Period: 20251231)
  • Filed with the SEC: March 23, 2026
  • Source: zk2634510.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001178913-26-001593

Figures are derived from filed reports and may be restated. Historical data is subject to revision.